Charles River unveils 'Pathway to Purpose' strategy; reaffirms 2026 guidance at upper end

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Announces 'Pathway to Purpose' strategy focused on modernization, scientific portfolio, and client-centric approach.
Expects over $300M cumulative savings from Create the Future program (2027-2030) via automation and AI digital tools.
Reaffirms 2026 guidance: organic revenue growth at upper end of 0%–1%; non-GAAP EPS at upper end of $11.15–$11.45.
Introduces 2030 targets: 5%–7% organic revenue CAGR, ~24% non-GAAP operating margin, low-double-digit EPS CAGR.
Bioanalysis revenue targeted at ~$450M by 2030; Apollo platform now serves 18,000 client users.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.